Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03703388 · ClinicalTrials.gov registry record · NA
The Safety and Intake Rate of a Natural Compound Arctigenin in Healthy Men
A NA study, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- NA
- Development phase
- 21
- Enrollment target
NCT03703388 is a NA study that has completed, run by University of California, Los Angeles. The registered enrollment target is 21 participants.
The verdict
NCT03703388, a NA study, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- NA
- Development phase
- 21 participants
- Enrollment target
Study Summary
The purpose of this research study is to determine if consuming arctigenin, a natural compound from a Chinese herb called Arctium lappa (commonly called greater burdock), is safe, and to measure the intake level of arctigenin in blood. Arctigenin is being studied by researchers for potential health benefits such as helping to lower the risk of inflammation and cancer. A human study has been done measuring the uptake of arctigenin into blood after consumption of the herb extract containing arctigenin, and found no toxicity. Studies in mice demonstrated that consumption of arctigenin in pure form at a safe level is highly effective in inhibition of prostate cancer growth. Therefore, this study is designed to evaluate the safety and uptake rate of pure arctigenin in humans, which may be potentially used in the future for prostate cancer prevention.
Interventions
- DIETARY_SUPPLEMENT Arctigenin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2019-01-15 |
| Est. Completion | 2020-07-15 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03703388
The ClinicalTrials.gov registry entry for NCT03703388 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Arctigenin is the first listed.
NCT03703388 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03703388 about?
NCT03703388 is a clinical study titled "The Safety and Intake Rate of a Natural Compound Arctigenin in Healthy Men". The purpose of this research study is to determine if consuming arctigenin, a natural compound from a Chinese herb called Arctium lappa (commonly called greater burdock), is safe, and to measure the intake level of arctigenin in blood. Arctigenin is being studied by researchers for potential health ...
What is the current status of trial NCT03703388?
This trial is currently completed. It is a NA study. The enrollment target is 21 participants. The study started on 2019-01-15. Estimated completion is 2020-07-15.
What interventions are being tested in trial NCT03703388?
The interventions under investigation include: Arctigenin (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03703388?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.